BDTX

BDTX

USD

Black Diamond Therapeutics Inc. Common Stock

$2.375+0.025 (1.064%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$2.350

Kõrge

$2.380

Madal

$2.300

Maht

0.56M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

135.0M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

3.50M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $1.195Praegune $2.375Kõrge $6.75

Seotud uudised

GlobeNewswire

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential

Vaata rohkem
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12

HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic with a Buy and raises the price target from $11 to $12.

Vaata rohkem
HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12
Analyst Upgrades

Stifel Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $15

Stifel analyst Bradley Canino maintains Black Diamond Therapeutic with a Buy and lowers the price target from $16 to $15.

Vaata rohkem
Stifel Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $15